MX2014002919A - Uso de 3-(r)-[3-(2-metoxifeniltio)-2-(s)-metilpropil] amino-3-dihidro-2h-1,5-benzoxatiepina para el tratamiento de cancer y, en particular para la prevencion y/o tratamiento de metastasis del cancer. - Google Patents

Uso de 3-(r)-[3-(2-metoxifeniltio)-2-(s)-metilpropil] amino-3-dihidro-2h-1,5-benzoxatiepina para el tratamiento de cancer y, en particular para la prevencion y/o tratamiento de metastasis del cancer.

Info

Publication number
MX2014002919A
MX2014002919A MX2014002919A MX2014002919A MX2014002919A MX 2014002919 A MX2014002919 A MX 2014002919A MX 2014002919 A MX2014002919 A MX 2014002919A MX 2014002919 A MX2014002919 A MX 2014002919A MX 2014002919 A MX2014002919 A MX 2014002919A
Authority
MX
Mexico
Prior art keywords
treating cancer
benzoxathiepine
methoxyphenylthio
methylpropyl
amino
Prior art date
Application number
MX2014002919A
Other languages
English (en)
Inventor
Bernard Vacher
Bruno Le Grand
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of MX2014002919A publication Critical patent/MX2014002919A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al uso de 3-(R)-[3-(2-metoxifenil tio)-2-(S)-metilpropil] amino-3-dihidro-2H-1,5-benzoxatiepina o cualquiera de las sales farmacéuticamente aceptables de la misma en el tratamiento del cáncer y en particular en la prevención y/o tratamiento de metástasis del cáncer.
MX2014002919A 2011-09-13 2012-09-12 Uso de 3-(r)-[3-(2-metoxifeniltio)-2-(s)-metilpropil] amino-3-dihidro-2h-1,5-benzoxatiepina para el tratamiento de cancer y, en particular para la prevencion y/o tratamiento de metastasis del cancer. MX2014002919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1158148A FR2979823B1 (fr) 2011-09-13 2011-09-13 Utilisation du 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methyl-propyl]amino-3,4-dihydro-2h-1,5-benzoxathiepine pour le traitement du cancer et en particulier pour la prevention et/ou le traitement des metastases cancereuses
PCT/EP2012/067780 WO2013037800A1 (fr) 2011-09-13 2012-09-12 Utilisation de la 3-(r)-[3-(2-methoxyphenylthio)-2-(s)-methyl-propyl]amino-3,4-dihydro-2h-1,5-benzoxathiepine pour le traitement du cancer et en particulier pour la prevention et/ou le traitement des metastases cancereuses

Publications (1)

Publication Number Publication Date
MX2014002919A true MX2014002919A (es) 2014-09-22

Family

ID=46875768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002919A MX2014002919A (es) 2011-09-13 2012-09-12 Uso de 3-(r)-[3-(2-metoxifeniltio)-2-(s)-metilpropil] amino-3-dihidro-2h-1,5-benzoxatiepina para el tratamiento de cancer y, en particular para la prevencion y/o tratamiento de metastasis del cancer.

Country Status (22)

Country Link
US (1) US9603835B2 (es)
EP (1) EP2755650B1 (es)
JP (1) JP5976813B2 (es)
KR (1) KR20140062496A (es)
CN (1) CN103764142B (es)
AU (1) AU2012307437B2 (es)
BR (1) BR112014005519A2 (es)
CA (1) CA2848017A1 (es)
ES (1) ES2556583T3 (es)
FR (1) FR2979823B1 (es)
HK (1) HK1193038A1 (es)
HU (1) HUE026337T2 (es)
IL (1) IL231424A (es)
MA (1) MA35710B1 (es)
MX (1) MX2014002919A (es)
MY (1) MY165039A (es)
PL (1) PL2755650T3 (es)
RU (1) RU2626511C2 (es)
TN (1) TN2014000066A1 (es)
UA (1) UA110857C2 (es)
WO (1) WO2013037800A1 (es)
ZA (1) ZA201402037B (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU642596B2 (en) * 1991-06-10 1993-10-21 Sanofi-Synthelabo Thioxanthenone antitumor agents
FR2822467B1 (fr) * 2001-03-22 2003-12-12 Pf Medicament Derives benzoxathiepines et leur utilisation comme medicaments
US8835473B2 (en) 2004-04-16 2014-09-16 Rutgers, The State University Of New Jersey Methods and compositions for treating cancer
FR2908132B1 (fr) * 2006-11-08 2008-12-19 Pierre Fabre Medicament Sa Procede de synthese du n-[3-[(2-methoxyphenyl)sulfanyl]-2- methylpropyl]-3,4-dihydro-2h-1,5-benzoxathiepin-3-amine
WO2012049439A1 (en) * 2010-10-13 2012-04-19 Imperial Innovations Limited Treatment of cancer/inhibition of metastasis

Also Published As

Publication number Publication date
PL2755650T3 (pl) 2016-03-31
EP2755650B1 (fr) 2015-10-07
IL231424A (en) 2016-12-29
AU2012307437A1 (en) 2014-04-10
CN103764142A (zh) 2014-04-30
NZ622728A (en) 2015-08-28
AU2012307437B2 (en) 2017-01-12
HUE026337T2 (hu) 2016-05-30
IL231424A0 (en) 2014-04-30
ES2556583T3 (es) 2016-01-19
MA35710B1 (fr) 2014-12-01
MY165039A (en) 2018-02-28
UA110857C2 (uk) 2016-02-25
US9603835B2 (en) 2017-03-28
ZA201402037B (en) 2015-03-25
CN103764142B (zh) 2015-11-25
KR20140062496A (ko) 2014-05-23
RU2626511C2 (ru) 2017-07-28
JP5976813B2 (ja) 2016-08-24
CA2848017A1 (fr) 2013-03-21
HK1193038A1 (zh) 2014-09-12
WO2013037800A1 (fr) 2013-03-21
US20140206743A1 (en) 2014-07-24
RU2014112785A (ru) 2015-10-20
FR2979823A1 (fr) 2013-03-15
BR112014005519A2 (pt) 2017-03-21
TN2014000066A1 (fr) 2015-07-01
EP2755650A1 (fr) 2014-07-23
JP2014526485A (ja) 2014-10-06
FR2979823B1 (fr) 2013-09-27

Similar Documents

Publication Publication Date Title
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
ZA201308617B (en) Use of thiazolide compounds for the prevention and treatment of viral diseases, cancer and diseases caused by intracellular infections
MX2013011332A (es) Combinaciones de compuestos inhibidores de akt y vemurafenib y metodos de uso de los mismos.
NZ724250A (en) Human plasma kallikrein inhibitors
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
MY183534A (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
NZ746054A (en) Methods of treating cancer
EP2424360A4 (en) TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
SG10201903119QA (en) Polypeptide vaccine
EA201290837A1 (ru) Лечение волчаночного нефрита с применением лаквинимода
IN2014DN10670A (es)
EP2671586A4 (en) PHARMACOTHERAPY FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
EA201390428A1 (ru) Композиции и способы лечения легочной гипертензии
SG195257A1 (en) Anti-thrombotic compounds
PH12015501088A1 (en) Dimeric compounds
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain
MX2014002919A (es) Uso de 3-(r)-[3-(2-metoxifeniltio)-2-(s)-metilpropil] amino-3-dihidro-2h-1,5-benzoxatiepina para el tratamiento de cancer y, en particular para la prevencion y/o tratamiento de metastasis del cancer.
WO2012158776A3 (en) Combination therapy for treatment of cancer
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
EP2755679A4 (en) IMMUNOGENS INDUCING CYTOTOXIC T LYMPHOCYTES FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF CANCER